Althea Group Holdings Ltd (ASX: AGH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Althea Group Holdings Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$87.90 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
262.37 million
Earnings per share
-0.062
Dividend per share
N/A
Year To Date Return
-24.14%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cannabis Shares
Here’s why ASX cannabis shares are lighting up today
Share Market News
How New Yorkers could send ASX cannabis shares higher
Cannabis Shares
Why the Althea (ASX:AGH) share price is on a high today
Share Market News
How Mexico could turbocharge ASX cannabis shares
Share Gainers
Why the Althea (ASX:AGH) share price is pushing higher today
Share Gainers
Why the Althea (ASX:AGH) share price is pushing higher today
Share Market News
Why the Althea (ASX:AGH) share price is surging 8% higher today
Share Gainers
Here’s why the Althea (ASX:AGH) share price is racing 8% higher today
AGH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Althea Group Holdings Ltd
One of Australia’s ASX cannabis shares, Althea Group Holdings Limited (ASX: AGH) cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia and the United Kingdom.
Althea also offers a range of education, access and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways.
Althea shares first listed on the ASX in September 2018. The AGH share price is tied to the global legal marijuana market, which has been spurred by increased legalisation and the use of marijuana in medical applications.
AGH Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 11 Jun 2021 | $0.33 | $0.01 | 3.08% | 268,411 | $0.34 | $0.34 | $0.33 |
| 10 Jun 2021 | $0.33 | $0.00 | 0.00% | 231,093 | $0.33 | $0.34 | $0.33 |
| 09 Jun 2021 | $0.33 | $0.00 | 0.00% | 613,876 | $0.33 | $0.33 | $0.33 |
| 08 Jun 2021 | $0.33 | $-0.02 | -5.88% | 778,895 | $0.34 | $0.34 | $0.33 |
| 07 Jun 2021 | $0.34 | $0.00 | 0.00% | 727,043 | $0.35 | $0.35 | $0.34 |
| 04 Jun 2021 | $0.35 | $-0.01 | -2.86% | 662,343 | $0.36 | $0.37 | $0.35 |
| 03 Jun 2021 | $0.35 | $-0.01 | -2.82% | 435,853 | $0.36 | $0.37 | $0.35 |
| 02 Jun 2021 | $0.36 | $-0.01 | -2.78% | 426,949 | $0.36 | $0.37 | $0.35 |
| 01 Jun 2021 | $0.36 | $0.00 | 0.00% | 461,656 | $0.36 | $0.37 | $0.36 |
| 31 May 2021 | $0.36 | $-0.01 | -2.74% | 183,686 | $0.37 | $0.37 | $0.36 |
| 28 May 2021 | $0.37 | $-0.01 | -2.67% | 248,715 | $0.38 | $0.38 | $0.37 |
| 27 May 2021 | $0.38 | $-0.01 | -2.63% | 80,965 | $0.39 | $0.39 | $0.38 |
| 26 May 2021 | $0.38 | $0.01 | 2.67% | 135,289 | $0.38 | $0.38 | $0.38 |
| 25 May 2021 | $0.38 | $-0.01 | -2.61% | 108,640 | $0.38 | $0.38 | $0.37 |
| 24 May 2021 | $0.38 | $0.00 | 0.00% | 82,506 | $0.38 | $0.39 | $0.38 |
| 21 May 2021 | $0.38 | $-0.01 | -2.56% | 111,290 | $0.39 | $0.39 | $0.38 |
| 20 May 2021 | $0.39 | $0.00 | 0.00% | 374,704 | $0.39 | $0.39 | $0.37 |
| 19 May 2021 | $0.39 | $0.00 | 0.00% | 402,343 | $0.39 | $0.39 | $0.37 |
| 18 May 2021 | $0.39 | $0.01 | 2.63% | 139,167 | $0.38 | $0.39 | $0.38 |
| 17 May 2021 | $0.38 | $-0.02 | -5.06% | 382,240 | $0.40 | $0.40 | $0.38 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 27 Jan 2021 | Alan Boyd | Buy | 68 | $30,000 |
Participation in share purchase plan.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Alan Maclean Boyd | Non-Executive Director | Jun 2018 |
Mr Boyd is the Chief Financial Officer and Company Secretary of Ridley Corporation Limited, an ASX-listed provider of high performance animal nutrition solutions. Prior to this role, Alan occupied the same position with listed biotechnology companies Avexa Limited and Zenyth Therapeutics Limited, website pioneer Sausage Software Limited, and unlisted public entity HRL Limited, where he later served as a non-executive director and Chair of the Audit Committee. Alan started his professional career in chartered accounting firms in England and Australia and has broad financial experience across many industry sectors. He is also serves on Risk and Compliance Management Committee.
|
| Mr Philip Andrew Newbold | Non-Executive ChairmanNon-Executive Director | Jun 2018 |
Mr Newbold founded a renewable energy business which he sold to Origin Energy in 2009. Since that time he has been involved in a start-up property app business which he sold to ANZ in 2015 and various other businesses. Andrew has been a director of numerous private companies and not-for-profit organisations and currently is a director of Supra Capital, a Commissioner of the AFL and Chairman of Golf Australia. He is also serves on Risk and Compliance Management Committee.
|
| Mr Joshua Michael Fegan | Chief Executive OfficerManaging Director | Jun 2018 |
Mr Fegan is Sales and Marketing Manager - Strathfield Group. Joshua has a range of proven business and strategy skills and has previously held a number of senior management roles at national value-based retailer, Strathfield Group. Joshua founded Althea Health and Wellbeing in 2016, coinciding with registration of the Narcotic Drugs Amendment Act 2016 (Cth) (ND Amendment Act), an Act to amend the Narcotic Drugs Act 1967 (Cth) (ND Act), legalising medicinal cannabis.
|
| Penelope Dobson | Non-Executive Director | Nov 2018 |
Ms Dobson is an experienced global healthcare executive. She has worked in the broad life-sciences space since her training as a pharmacist in New Zealand, including many years in the global pharmaceutical industry. Penny is currently principal of Valida Consulting, offering a range of services to companies in the healthcare, Pharma, Biotech, Not for Profit, Device and Diagnostics sector. She is also serves on Risk and Compliance Management Committee.
|
| Mr Robert Meissner | Chief Financial OfficerCompany Secretary | Apr 2019 |
-
|
| Robert Meissner | Chief Financial OfficerCompany Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Joshua Michael Fegan | 56,250,000 | 24.11% |
| HSBC Custody Nominees (Australia) Limited | 19,560,597 | 8.38% |
| Aphria Inc. | 12,250,000 | 5.25% |
| Mancann Pty Ltd | 10,000,000 | 4.29% |
| Hootch Pty Ltd | 7,500,000 | 3.21% |
| National Nominees Limited | 5,347,880 | 2.29% |
| Ubs Nominees Pty Ltd | 3,579,819 | 1.53% |
| PAC Partners Pty Ltd | 3,242,347 | 1.39% |
| Citicorp Nominees Pty Limited | 3,073,088 | 1.32% |
| Mr Philip John Cawood | 1,800,000 | 0.77% |
| Newbold Family Super Fund | 1,500,000 | 0.64% |
| Mansfield Can Investments Pty Ltd (Mansfield Super Fund A/C) | 1,366,035 | 0.59% |
| PAC Partners Securities Pty Ltd | 1,337,555 | 0.57% |
| BNP Paribas Nominees Pty Ltd (IOOF INSMT MGMT LTD DRP) | 1,300,000 | 0.56% |
| Maelstrom Pty Ltd (Falkiner Super Fund A/C) | 1,200,000 | 0.51% |
| Sandhurst Trustees Ltd (Cyan C3G Fund A/C) | 931,666 | 0.40% |
| J P Morgan Nominees Australia Pty Limited | 817,239 | 0.35% |
| RMO Holdings Ltd | 750,000 | 0.32% |
| Mrs Margaret Lynette Harvey | 650,000 | 0.28% |
| Mr Shane Trevor Kennedy | 550,000 | 0.24% |
Frequently Asked Questions
-
Althea Group does not currently pay a dividend.
-
No, Althea Group doesn’t currently offer a dividend reinvestment plan (DRP).